such as common juniper or extracts thereof are useful as pharmaceuticals, food, or cosmetics that exert slimming effects such as suppression, prevention, or improvement of obesity, by promoting decomposition of triglycerides accumulated in adipose tissue (Patent Literature 3). However, the lipolysis effects and weight loss effects of these plant extracts and the like cannot be regarded sufficient at present. Moreover, Patent Literature 4 discloses that a composition containing a combination of a hydrophobic extract of licorice with an antioxidant component or the like exerts suppressing effects on body fat accumulation, promoting decomposition of body fat, and enhancing energy production, but a sufficient lipolysis promoting effect cannot be achieved by the hydrophobic extract of licorice alone.

CITATION LIST

Patent Literature

[0005] Patent Literature 1: JP 2011-074051 A
Patent Literature 2: JP 2006-045120 A
Patent Literature 3: JP 2012-229266 A
Patent Literature 4: WO2008/143182

SUMMARY

Technical Problem

[0006] A problem to be solved by the present disclosure is to provide a novel formulation excellent in a lipolysis promoting effect, a visceral fat/body fat reducing effect, a weight reducing effect, and a BMI improving effect. Another object of the present disclosure is to provide a novel formulation excellent in an improving effect on insulin resistance, a reducing effect on cholesterol levels, and the like.

Solution to Problem

[0007] The present inventors have found, as a result of intensive studies, that "Glyasperin B", that is, a specific component contained in licorice extract, exhibits excellent lipolysis promoting activity. The inventors have also found that a formulation containing licorice extract containing Glyasperin B exerts, in addition to an excellent lipolysis promoting effect, a visceral fat/body fat reducing effect, a weight reducing effect, a BMI improving effect, an insulin resistance improving effect, and a cholesterol level lowering effect. Moreover, the inventors have found that the content of Glyasperin B in a plant extract can be used as an indicator of the efficacy of the plant extract for lipolysis, weight loss, and the like. The gist of the present disclosure is as follows:

[0008] [1] An oral composition comprising Glyasperin B, for use in one or more of:

lipolysis, fat burning, support of fat consumption, BMI improvement, support of BMI reduction, abdominal fat reduction, visceral fat reduction, body fat reduction, waist circumference reduction, improvement of insulin resistance, and reduction of LDL cholesterol level.

[2] An oral composition comprising an effective amount of Glyasperin B, for use in one or more of: lipolysis, fat burning, support of fat consumption, BMI improvement, support of BMI reduction, abdominal fat reduction, visceral fat reduction, body fat reduction, waist circumference reduction, improvement of insulin resistance, and reduction of LDL cholesterol level.

[3] The oral composition according to [2], wherein the effective amount is 10 μg or more per day for an adult.

[4] The oral composition according to [1] or [2], for use in an adult having a BMI of 23 kg/m^2 or more and less than 30 kg/m^2.

[5] The oral composition according to [1] or [2], for use for an adult having a visceral fat area of 100 cm^2 or more.

[6] The oral composition according to [1] or [2], wherein the oral composition is ingested at a dosage of 5 to 100 μg/day, calculated as a total amount of Glyasperin B.

[7] A method for determining efficacy of a plant extract for lipolysis and/or weight loss in a living body, wherein the content of Glyasperin B is used as an indicator.

[8] The method for determining efficacy of a plant extract for lipolysis and/or weight loss according to [7], wherein the plant is licorice.

[9] An indicator of a quality of a plant extract, wherein the quality relates to efficacy for lipolysis and/or weight loss in a living body, and the indicator comprises Glyasperin B.

[10] The indicator according to [9], wherein the plant is licorice.

[0008a] In an aspect, there is provided use of an oral composition comprising Glyasperin B in the manufacture of a medicament for use in one or more of: lipolysis, fat burning, support of fat consumption, BMI improvement, support of BMI reduction, abdominal fat reduction, visceral fat reduction, body fat reduction, waist circumference reduction, improvement of insulin resistance, and reduction of LDL cholesterol levels.

[0008b] In another aspect, there is provided a method for determining efficacy of a plant extract for lipolysis and/or weight loss in a living body, wherein the content of Glyasperin B is used as an indicator.

[0008c] In another aspect, there is provided use of Glyasperin B as an indicator of a quality of a plant extract, wherein the quality relates to efficacy for lipolysis and/or weight loss in a living body.

[0008d] In another aspect, there is provided a non-therapeutic method for use in one or more of: lipolysis, fat burning, support of fat consumption, BMI improvement, support of BMI reduction, abdominal fat reduction, visceral fat reduction, body fat reduction, waist circumference reduction, improvement of insulin resistance, and reduction of LDL cholesterol levels, comprising administering an oral composition comprising Glyasperin B to a subject.

Advantageous Effects

[0009] An oral composition of the present disclosure possesses, by containing Glyasperin B, preferably as an active ingredient, a functionally relevant component, an indicator component, or a contributing component, excellent lipolysis promoting activity and also exerts a remarkable weight reducing effect. By using the oral composition of the present disclosure, fat within adipocytes can be efficiently decomposed, and body fat such as subcutaneous fat and visceral fat can be reduced, resulting in remarkable weight reducing effect and BMI improving effect. Furthermore, improving effects on insulin resistance and lowering effects on cholesterol levels can also be obtained. Therefore, the oral composition of the present disclosure makes it possible to prevent or ameliorate obesity and lifestyle diseases over a long term, and thus, maintenance and promotion of health can be realized. Furthermore, since the

CLAIMS

[Claim 1] Use of an oral composition comprising Glyasperin B in the manufacture of a medicament for use in one or more of: lipolysis, fat burning, support of fat consumption, BMI improvement, support of BMI reduction, abdominal fat reduction, visceral fat reduction, body fat reduction, waist circumference reduction, improvement of insulin resistance, and reduction of LDL cholesterol levels.

[Claim 2] The use according to claim 1, wherein the oral composition is to be administered to an adult having a BMI of 23 kg/m^2 or more and less than 30 kg/m^2.

[Claim 3] The use according to claim 1, wherein the oral composition is to be administered to an adult having a visceral fat area of 100 cm^2 or more.

[Claim 4] The use according to claim 1, wherein the oral composition is to be ingested at a dosage of 5 to 100 μg/day, calculated as a total amount of Glyasperin B.

[Claim 5] A method for determining efficacy of a plant extract for lipolysis and/or weight loss in a living body, wherein the content of Glyasperin B is used as an indicator.

[Claim 6] The method according to claim 5, wherein the plant is licorice.

[Claim 7] Use of Glyasperin B as an indicator of a quality of a plant extract, wherein the quality relates to efficacy for lipolysis and/or weight loss in a living body.

[Claim 8] The use according to claim 7, wherein the plant is licorice.

[Claim 9] A non-therapeutic method for use in one or more of: lipolysis, fat burning, support of fat consumption, BMI improvement, support of BMI reduction, abdominal fat reduction, visceral fat reduction, body fat reduction, waist circumference reduction, improvement of insulin resistance, and reduction of LDL cholesterol levels, comprising administering an oral composition comprising Glyasperin B to a subject.

[Claim 10] The method according to claim 9, wherein the subject is an adult having a BMI of 23 kg/m^2 or more and less than 30 kg/m^2.

[Claim 11] The method according to claim 9, wherein the subject is an adult having a visceral fat area of 100 cm^2 or more.

[Claim 12] The method according to claim 9, wherein the oral composition is ingested by the subject at a dosage of 5 to 100 μg/day, calculated as a total amount of Glyasperin B.